Literature DB >> 15757479

Novel strategies for prevention and treatment of influenza.

Ruth Kandel1, Kevan L Hartshorn.   

Abstract

Influenza viruses continue to be a major health challenge due to antigenic variation in envelope proteins and animal reservoirs for the viruses. Of particular concern is an anticipated influenza pandemic in the near future. Vaccination is currently the most effective means of reducing morbidity and mortality during influenza epidemics. In addition, neuraminidase inhibitors have substantially improved antiviral therapy for influenza. However, influenza infection in children and the elderly remain problematic. Furthermore, major innovations in prevention and therapy will be needed to deal with an influenza pandemic. This review assesses available and investigational antivirals and vaccines for influenza, emphasising novel approaches that may improve ability to cope with infection in children and the elderly or during a pandemic. Some adverse sequelae of influenza appear to relate to impairment or pathogenic activation of immune responses. Exciting recent findings in this area, with relevance to influenza treatment, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757479     DOI: 10.1517/14728222.9.1.1

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  10 in total

1.  New look at an old problem: bacterial superinfection after influenza.

Authors:  Kevan L Hartshorn
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 2.  Influenza vaccination in children being treated with chemotherapy for cancer.

Authors:  Ginette M Goossen; Leontien C M Kremer; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01

3.  Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia.

Authors:  Marieke A D van Zoelen; Koenraad F van der Sluijs; Ahmed Achouiti; Sandrine Florquin; Jennie M Braun-Pater; Huan Yang; Peter P Nawroth; Kevin J Tracey; Angelika Bierhaus; Tom van der Poll
Journal:  Virology       Date:  2009-07-09       Impact factor: 3.616

4.  Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

Authors:  Olivia Perwitasari; Xiuzhen Yan; Scott Johnson; Caleb White; Paula Brooks; S Mark Tompkins; Ralph A Tripp
Journal:  Antimicrob Agents Chemother       Date:  2012-11-05       Impact factor: 5.191

5.  Multiple components contribute to ability of saliva to inhibit influenza viruses.

Authors:  M R White; E J Helmerhorst; A Ligtenberg; M Karpel; T Tecle; W L Siqueira; F G Oppenheim; K L Hartshorn
Journal:  Oral Microbiol Immunol       Date:  2009-02

6.  Inhibition of hemagglutination activity of influenza A viruses by SP-A1 and SP-A2 variants expressed in CHO cells.

Authors:  Anatoly N Mikerov; Mitch White; Kevan Hartshorn; Guirong Wang; Joanna Floros
Journal:  Med Microbiol Immunol       Date:  2007-05-23       Impact factor: 3.402

7.  Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia.

Authors:  Ronan Le Goffic; Viviane Balloy; Micheline Lagranderie; Lena Alexopoulou; Nicolas Escriou; Richard Flavell; Michel Chignard; Mustapha Si-Tahar
Journal:  PLoS Pathog       Date:  2006-06-09       Impact factor: 6.823

Review 8.  Potential Role of MicroRNAs in the Regulation of Antiviral Responses to Influenza Infection.

Authors:  Thi Hiep Nguyen; Xiaoming Liu; Zhen Zhong Su; Alan Chen-Yu Hsu; Paul S Foster; Ming Yang
Journal:  Front Immunol       Date:  2018-07-04       Impact factor: 7.561

9.  Baicalin inhibits influenza virus A replication via activation of type I IFN signaling by reducing miR‑146a.

Authors:  Rui Li; Lianxin Wang
Journal:  Mol Med Rep       Date:  2019-10-15       Impact factor: 2.952

10.  siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.

Authors:  Olivia Perwitasari; Abhijeet Bakre; S Mark Tompkins; Ralph A Tripp
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.